2月5日，荃信生物-B(02509)盘中下跌31.8%，截至14:55，报6.07元/股，成交103.91万元。
江苏荃信生物医药股份有限公司的主营业务是研发自身免疫及过敏性疾病的生物疗法。公司现有1个品种BLA已受理，1个品种处于临床3期，4个品种分别处于临床2期及1期，产品覆盖皮肤、风湿、呼吸、消化等领域，拥有及申报的国内外专利达90余项。
截至2024年中报，荃信生物-B营业总收入4491.9万元、净利润-1.72亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.